Skip to content

The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection

The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04675723
Enrollment
52
Registered
2020-12-19
Start date
2019-09-23
Completion date
2022-05-05
Last updated
2023-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clostridioides Difficile Infection

Brief summary

The study is being done to identify types of bacteria associated with the lining of the large intestine in people who have recently been treated for C. difficile infection to determine if there are features associated with recurrent disease.

Detailed description

Patients who have recently been diagnosed with C. difficile infection and completed treatment will be enrolled to undergo evaluation of the colonic mucosa via sigmoid biopsies. Participants will also complete surveys, blood draw and stool collection. Overall goals are to identify whether C. difficile is persisting in the colon mucosa after treated infection, and whether this, and other clinical and microbiome factors may be playing a role in disease recurrence.

Interventions

None listed

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 and over * Confirmed C. difficile infection based on positive C. difficile toxin PCR testing and clinical evidence of diarrhea

Exclusion criteria

* Known pregnancy * Prior diagnosis of C. difficile infection within 2 months of this diagnosis * Other known active gastrointestinal infectious process * Known diagnosis of inflammatory bowel disease, microscopic colitis, celiac disease or other inflammatory conditions * Vulnerable adults * Any other disease(s), condition(s) or habit(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.

Design outcomes

Primary

MeasureTime frameDescription
Mucosal presence1-14 days post C. Difficile treatmentIdentification of C. difficile within the colonic mucosa on stained slides from biopsy samples
Disease recurrence8 weeksDetermination of recurrent C. difficile infection based on symptoms and potential clinical testing

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026